X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
With the anticipated acquisition of Abveris, Twist will have expertise in each, creating a robust antibody design, discovery and screening organization to serve both its partners and internal pipeline.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Twist Bioscience
Deal Size: $190.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition November 22, 2021
Details:
Abveris will utilize its proprietary DiversimAbTM mouse model in combination with its next-generation B cell screening platform, powered by the Berkeley Lights Beacon®, to rapidly discover monoclonal antibodies for use as research reagents and therapeutics for immuno-oncology.
Lead Product(s): Monoclonal antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Berkeley Lights
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 08, 2020
Details:
Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse®, an industry-leading transgenic mouse R&D platform.
Lead Product(s): Human monoclonal antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nkarta
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
